Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilpivirine in ARV-Naive HIV-1 Infected Children < 12 Years
NCT01975012Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Sep 2014; status: withdrawn.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01975012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01975012.